Your session is about to expire
← Back to Search
Mitapivat for Thalassemia (ENERGIZE Trial)
ENERGIZE Trial Summary
This trial will compare the effect of the drug mitapivat versus placebo on anemia in people with either alpha- or beta-non-transfusion dependent thalassemia.
ENERGIZE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowENERGIZE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ENERGIZE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not needed more than 5 blood transfusions in the last 6 months and none in the last 2 months.I do not have any health conditions that my doctor thinks would make this study unsafe for me.I am allergic to mitapivat or its ingredients.I have had cancer within the last 5 years.I haven't had blood cell boosters in the last 18 weeks.I have not taken strong CYP3A4/5 inhibitors or inducers for the required time before joining.I haven't had serious heart or lung problems in the last 6 months.I have been diagnosed with thalassemia based on specific blood tests or DNA analysis.My hydroxyurea dose has been the same for at least 16 weeks.My kidney function is reduced, with an eGFR below 45 mL/min/1.73m^2.I have not had major surgery in the last 16 weeks and do not plan any during the study.I have been treated with luspatercept, and my last dose was over 18 weeks ago.I have a documented history of sickle cell disease.I have a liver or bile duct disorder.I have had gene therapy or a bone marrow/stem cell transplant before.My average hemoglobin level is 10 g/dL or less, based on at least 2 tests a week apart.I haven't taken anabolic steroids in the last 4 weeks, but I may be on stable testosterone treatment for low testosterone.
- Group 1: Mitapivat
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any other instances where Mitapivat has been used in a medical capacity?
"The first clinical trial for mitapivat was conducted in 2015 at Stanford University. In the intervening years, there have been a total of 12 completed trials. As of right now, there are 9 active studies being conducted; many of these taking place within New york City."
Are we currently taking applications for this test?
"That is correct, the listing on clinicaltrials.gov does show that this trial is still recruiting patients. This particular study was posted on November 8th, 2021 and was edited on the same date one year later. They are looking for a total of 171 individuals from 12 different locations to participate."
Is this trial common in American hospitals?
"12 clinical trial sites are presently recruiting patients for this study. They are based in New york, Palo Alto and Philadelphia as well as 12 other locations. To minimize travel demands, you should select the site closest to you if you participate."
Has the FDA given Mitapivat their blessing?
"Mitapivat's safety is estimated to be a 3. This comes from the fact that it is a Phase 3 trial, meaning that there are data supporting efficacy and multiple rounds of data supporting safety."
Share this study with friends
Copy Link
Messenger